Why Is ALNYLAM PHARMACEUTIC (ALNY) Stock Up Today?

ALNY stock is up 7.67% at $264.98 as of the latest trade, driven by renewed investor interest in the company’s drug development pipeline and a reiteration of a positive analyst rating. The stock has surged from an opening price of $246.51 to a session high of $267.22, with volume reaching 0.7 million shares, more than half of its 3-month daily average. The move follows recent updates on clinical data and a webcast announcement for investor conferences.

What Happened

Alnylam Pharmaceuticals is set to present new clinical and real-world data at the 2026 ESC Congress, focusing on its transthyretin-mediated amyloidosis and hypertension programs. This comes alongside the company’s announcement of a webcast for investor conferences in September, which has drawn attention to its long-term strategic outlook. H.C. Wainwright reiterates its Buy rating for ALNY, citing the company’s drug differentiation and maintaining a $455 price target. These developments have contributed to a positive sentiment among investors, particularly in light of the recent AMVUTTRA results and a new RNAi approach for treating high blood pressure.

What The Data Shows

The stock has traded between $197.81 and $495.55 over the past 52 weeks and is currently trading near the upper end of that range. With a market cap of $32.2 billion and a P/E ratio of 43.8, Alnylam is positioned as a high-growth biotech firm. Revenue has grown 95.1% in the trailing twelve months, and the company maintains a net margin of 16.1%. The stock has also printed 15 fresh 52-week highs on September 2, 2026. Over the last eight sessions, the stock has risen 0.8% from $236.22 to $238.16, showing a gradual upward trend. Volume has been elevated, though not at extreme levels.

What To Watch

The company has not announced an upcoming earnings date. Investors should monitor the breadth of coverage and any further analyst commentary following the webcast presentations at the September investor conferences.